Arcutis And Huadong Announce Strategic Collaboration And Licensing Agreement For Topical Roflumilast In Greater China And Southeast Asia; Arcutis To Receive $30M Upfront Payment And Eligible To Receive Additional Payments
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics has entered into a strategic collaboration and licensing agreement with Huadong Medicine for the development and commercialization of topical Roflumilast in Greater China and Southeast Asia. Arcutis will receive an upfront payment of $30 million and is eligible for additional development and commercial milestone payments, as well as double-digit tiered royalties.
August 10, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcutis Biotherapeutics' new partnership with Huadong Medicine could potentially increase its revenue through the upfront payment, milestone payments, and royalties.
The news of Arcutis' partnership with Huadong Medicine is directly relevant to the company and its financial outlook. The upfront payment of $30 million provides immediate revenue, while the potential for additional milestone payments and royalties could significantly increase revenue in the future. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100